CRISM Therapeutics Corporation (AIM:CRTX)

Market Cap	7.13M +62.1%
Revenue (ttm)	352.00K +1,308.0%
Net Income	-2.39M
EPS	-0.05
Shares Out	79.19M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	25,000
Open	9.00
Previous Close	9.00
Day's Range	8.50 - 9.00
52-Week Range	8.00 - 18.50
Beta	0.59
Analysts	n/a
Price Target	n/a
Est. Earnings	Dec 22, 2026

About CRISM Therapeutics

CRISM Therapeutics Corporation develops a drug delivery technology for the clinical performance of cancer treatments for solid tumors through the local delivery of chemotherapy drugs in the British Virgin Islands. The company’s lead product is ChemoSeed, which can be implanted directly into the tumour or the resection margin following the removal of a tumour. It also provides formulation and consultancy services. The company was formerly known as Amur Minerals Corporation and changed its name to CRISM Therapeutics Corporation in May 2024. CRISM...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Employees: 4
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: CRTX

Financial Performance

In 2025, CRISM Therapeutics's revenue was 231,000, an increase of 824.00% compared to the previous year's 25,000. Losses were -1.90 million, 213.5% more than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 16, 2026

Data Sources Report a data error